NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
August 15, 2026 — SpecialtyRx, the largest privately owned long-term care pharmacy, showcased its national reach at FHCA 2026 with a prominent booth. Learn how Purple Exhibits helped them stand out.
August 15, 2026 — Comprehensive review of surgical strategies for necrotizing enterocolitis (NEC) in premature infants compares peritoneal drainage vs laparotomy, highlights bowel-preserving techniques, and evaluates emerging adjuncts to improve outcomes.
August 15, 2026 — AZ Drug Testing opens new Tucson site, expanding to 7 AZ locations and 10,000+ national collection sites for DOT drug and alcohol testing, ensuring compliance and convenience.
August 14, 2026 — Helix BioPharma announces board changes: CEO Thomas Mehrling appointed as director, Janusz Grabski resigns. Governance reshaped to support pipeline progress in oncology.
August 14, 2026 — Vycor Medical reports Q2 2026 financials: VBAS revenue dips 17% in international markets, NovaVision grows 17%. New studies support VBAS safety and efficacy. OTCQB: VYCO.
August 14, 2026 — Onco-Innovations advances ONC010, a nanoparticle PNKP inhibitor, with key manufacturing and metabolism studies, moving closer to first-in-human trials for biomarker-selected cancers.
August 14, 2026 — SS Innovations reports record Q2 2026 revenue of $13.9M, up 39.4%, with SSi Mantra installations rising 30.4%. Telesurgery milestone achieved. FDA decision expected by Q1 2027.
August 14, 2026 — Regentis Biomaterials secures Japanese patent for GelrinC, a cell-free hydrogel for knee cartilage repair, boosting IP protection and commercial scalability in major markets.
August 14, 2026 — Regentis Biomaterials' GelrinC hydrogel implant receives European approval for scalable manufacturing, advancing knee cartilage repair with off-the-shelf treatment, Phase III trial 50% enrolled.
August 14, 2026 — Discover how overlooked gamma-delta T cells are crucial in fighting cancer, potentially enhancing immunotherapy. Learn about implications for companies like Calidi Biotherapeutics.
August 14, 2026 — Quantum BioPharma reports Q2 2026 results: 53% cut in operating expenses, FDA approves IND for Lucid-MS Phase 2 trial in progressive MS, cash runway to 2027.
August 14, 2026 — Regentis Biomaterials (RGNT) passes 50% enrollment in Phase III SAGE study of GelrinC, advances European commercial rollout, and scales manufacturing 400%.
August 14, 2026 — HeartBeam (NASDAQ: BEAT) reports Q2 2026 results, completing enrollment in ALIGN-ACS study, advancing 12-lead ECG patch, and launching commercial sales.
August 14, 2026 — Lantern Pharma reports Q2 2026 results: AI oncology pipeline advances, OMAI spin-off, withZeta.ai launch, LP-300 and LP-184 progress, financials improved.
August 14, 2026 — Helus Pharma completes Phase 3 enrollment for depression drug HLP003, reports Q2 financials, and advances pipeline. Learn about the latest updates and impact.
August 14, 2026 — No Agenda 1894: Fauci's private doubts, vaccine miscarriage rates, Iran economic war, AI bubble, and more. Independent analysis of media deceptions.
August 14, 2026 — Learn how to get affordable dental implants in 2026 with our guide. Compare costs, avoid hidden fees, and save money on quality implant treatment.
August 14, 2026 — DM Clinical Research marks 20 years of expanding clinical trial access, with 35+ sites, 1.97M patients, and 35,000+ enrollments. Celebrating 'Champions of Clinical Research'.
August 13, 2026 — NeOnc Technologies' NEO100 shows positive Phase 2a results in recurrent brain cancer, with median OS of 26 months. FDA Type B meeting planned for registrational path.
August 13, 2026 — Quantum BioPharma's Lucid-MS targets disability drivers in MS beyond relapse rates, focusing on myelin preservation and functional recovery to combat progression independent of relapse activity.